MedTrace Logo

ExoLuminate Study for Early Detection of Pancreatic Cancer

NCT05625529 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-07-28

No results posted yet for this study

Summary

ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC).

Those with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, and a personal or family history of pancreatitis.

The goal of the study is to compare the performance of ExoVerita™ assay in early detection of PDAC to current standard-of-care methods of surveillance.

Conditions

  • Pancreas Cancer
  • Exosomes
  • Extracellular Vesicles
  • Pancreatic Neoplasms

Sponsors & Collaborators

  • Biological Dynamics

    lead INDUSTRY

Principal Investigators

  • Harmeet Dhani, MD, M.Sc · Biological Dynamics

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-19
Primary Completion
2028-01-01
Completion
2028-01-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05625529 on ClinicalTrials.gov